Commitment to Excellence: Over 50 Years of Leadership in API Development and Manufacturing ...

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of ...

The Annual General Meeting acknowledged the management's report on Zealand Pharma's activities in the past financial year and Zealand Pharma's audited Annual Report for 2024 was approved. The Annual ...

Inspired by high-level business forums such as the World Economic Forum and the JP Morgan Health Summit, Nutrify Today’s ...

Urteste plans to start clinical trials for its pancreatic cancer test in Europe in Q3 2025 ...

In connection with the reverse share split, the Company's shares will be transferred to a new ISIN. Please note the following key information for the change of ISIN: - Issuer: Zelluna ASA - Previous ...

Bagsværd, Denmark, 27 March 2025 - Today, Novo Nordisk A/S held its Annual General Meeting.

With NervPulse Therapy, Curonix continues to advance the field of PNS therapy by delivering targeted, nerve-specific programming that enhances outcomes and transforms the patient experience. To learn ...

Building the world’s largest biobank with data from global populations to accelerate biomarker and drug discovery and development of next-generation diagnostics. Secured $25M in funding from F-Prime, ...

WARMINSTER, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, ...

OCALA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the fourth quarter and full year 2024 and ...

An archived copy of the webcast will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.